Heterogeneity in the Magnitude of the Insulin Gene Effect on HLA Risk in Type 1 Diabetes
- Costantino Motzo1,
- Daniela Contu1,
- Heather J. Cordell2,
- Rosanna Lampis1,
- Mauro Congia1,
- Maria Giovanna Marrosu3,
- John A. Todd2,
- Marcella Devoto4 and
- Francesco Cucca15
- 1Dipartimento di Scienze Biomediche e Biotecnologie, Universita’ di Cagliari, Sardinia, Italy
- 2Juvenile Diabetes Research Foundation/Wellcome Trust Diabetes and Inflammation Laboratory, Cambridge Institute for Medical Research, University of Cambridge, Addenbrooke’s Hospital, Cambridge, U.K
- 3Centro Sclerosi Multipla, Dipartimento di Neuroscienze, Universita’ di Cagliari, Sardinia, Italy
- 4Department of Research, Nemours Children’s Clinic, Wilmington, DE, and the Dipartimento di Oncologia, Biologia, e Genetica, Universita’ di Genova, Genova, Italy
- 5Centro di Genetica Clinica, Dipartimento di Scienze Biomediche, Universita’ di Sassari, Sassari, Italy
- Address correspondence and reprint requests to Francesco Cucca, Universita’ di Cagliari, Dipartimento di Scienze Biomediche e Biotecnologie, Via Jenner, Cagliari, 09124 Italy. E-mail: fcucca{at}mcweb.unica.it
Abstract
There is still uncertainty concerning the joint action of the two established type 1 diabetes susceptibility loci, the HLA class II DQB1 and DRB1 genes (IDDM1) and the insulin gene (INS) promoter (IDDM2). Some previous studies reported independence, whereas others suggested heterogeneity in the relative effects of the genotypes at these disease loci. In this study, we have assessed the combined effects of the HLA-DQB1/DRB1 and INS genotypes in 944 type 1 diabetic patients and 1,023 control subjects, all from Sardinia. Genotype variation at INS significantly influenced disease susceptibility in all HLA genotype risk categories. However, there was a significant heterogeneity (P = 2.4 × 10−4) in the distribution of the INS genotypes in patients with different HLA genotypes. The INS predisposing genotype was less frequent (74.9%) in high-risk HLA genotype–positive patients than in those with HLA intermediate-risk (86.1%) and low-risk (84.8%) categories. Gene-gene interaction modeling led to rejection of the additive model, whereas a multiplicative model showed a better, albeit still partial, fit to the observed data. These genetic results are consistent with an interaction between the protein products of the HLA and INS alleles, in which both the affinity of the various HLA class II molecules for a preproinsulin-derived peptide and the levels of this peptide in the thymus act jointly as key regulators of type 1 diabetes autoimmunity.
- AFBAC, affected family-based control subject
- AR, absolute risk
- MHC, major histocompatibility complex
- P/C ratio, patient/control ratio
- POR, pairwise odds ratio
- PPI, preproinsulin
Footnotes
-
C.M. and D.C. contributed equally to this work.
-
Additional information for this article can be found in an online appendix at http://diabetes.diabetesjournals.org.
-
- Accepted September 3, 2004.
- Received May 26, 2004.
- DIABETES











